Humanigen Announces Participation and Presentation at Multiple Conferences in November

Rhea-AI Summary

Humanigen (NASDAQ: HGEN), a clinical-stage biopharmaceutical company, announced participation in several investor conferences in November 2021. CEO Cameron Durrant will present at the Credit Suisse 30th Annual Healthcare Conference on November 9 and participate in the Reuters Total Health Global Conference on November 18. COO and CFO Timothy Morris will present at the Jefferies London Healthcare Conference on November 17. Humanigen is developing lenzilumab to treat cytokine storm related to COVID-19 and other inflammatory conditions, with a rolling review submitted to the UK regulatory authority.

Positive

• Participation in multiple investor conferences may enhance visibility and investor interest.
• Lenzilumab is in advanced stages, with a Phase 3 LIVE-AIR study showing positive results.
• Rolling review for lenzilumab submitted to the UK regulatory authority, indicating potential for future commercialization.

Negative

• Dependence on external partners for product development could pose risks.
• Company operates without profitability, requiring additional capital for growth.
• Risks associated with the uncertainties of regulatory approvals and product launches.

BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that management will present and participate at multiple investors conferences in November 2021. Details of the conferences are as follows:

Credit Suisse 30^th Annual Healthcare Conference
Cameron Durrant, Chairman & CEO, will provide a corporate presentation at 8:00am EST on November 9, 2021. A livestream will be available via the link below and a webcast link to a recording of the event will be posted to the “Events and Presentations” section of Humanigen’s investor relations website after the event.

Webcast: https://kvgo.com/cs-2021-healthcare-conf/humanigen-inc-november
The webcast will be archived for up to one year under the Investor Relations section of the company’s website at www.ir.humanigen.com

Jefferies London Healthcare Conference
Timothy Morris, COO and CFO, will make a corporate presentation at 12:40pm EST on November 17, 2021. A livestream will be accessible via the link below and a webcast link to a recording of the event will be posted to the “Events and Presentations” section of Humanigen’s investor relations website after the event.

Webcast: https://wsw.com/webcast/jeff201/hgen/1823004
The webcast will be available for 90 days under the Investor Relations section of the company’s website at www.ir.humanigen.com

Reuters Total Health Virtual Global Conference
Cameron Durrant, Chairman & CEO, will participate in the Breakthrough Medical Innovation portion of the Reuters Total Health Global Conference on November 18, 2021. For more information, please access the event agenda at https://reutersevents.com/events/healthcare/conference-agenda.php

About Humanigen
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’. Lenzilumab is a first-in class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). Results from preclinical models indicate GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines involved in the cytokine storm. Early in the COVID-19 pandemic, investigation showed high levels of GM-CSF secreting T cells were associated with disease severity and intensive care unit admission. Humanigen’s Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent consequences of a full-blown cytokine storm in hospitalized patients with COVID-19. Humanigen has submitted lenzilumab to Medicines and Health Regulatory Agency in the United Kingdom for a rolling review towards potential Marketing Authorization. Humanigen is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 and CD19-targeted CAR-T cell therapies and is also exploring the effectiveness of lenzilumab in other inflammatory conditions such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis. For more information, visit www.humanigen.com and follow Humanigen on LinkedIn, Twitter, and Facebook.

Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward- looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our plans relating to lenzilumab.

Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections of our latest annual and quarterly reports and other filings with the SEC.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. We undertake no obligation to revise or update any forward-looking statements made in this presentation to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005544/en/

Humanigen Investor Relations

Ken Trbovich

Humanigen

trbo@humanigen.com

650-410-3206

Source: Humanigen, Inc.

FAQ

What investor conferences is Humanigen (HGEN) participating in November 2021?

Humanigen will attend the Credit Suisse 30th Annual Healthcare Conference on November 9, the Jefferies London Healthcare Conference on November 17, and the Reuters Total Health Global Conference on November 18, 2021.

What is the focus of Humanigen's development efforts?

Humanigen is focused on preventing and treating cytokine storms, particularly related to COVID-19, with its lead product, lenzilumab.

What key events related to lenzilumab are happening in November 2021?

Humanigen's management will present at several conferences and has submitted lenzilumab for review by the UK regulatory authority.

How does Humanigen's Phase 3 LIVE-AIR study impact its business outlook?

The Phase 3 LIVE-AIR study suggests that early intervention with lenzilumab may prevent severe outcomes associated with cytokine storms in COVID-19 patients, which could enhance the company's market position.

What financial challenges does Humanigen (HGEN) face?

Humanigen faces financial challenges due to its lack of profitability and reliance on external capital for growth.